Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL0120 in Chronic Kidney Disease
NCT07716618Phase 2Active, not recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jan 2025
- Primary completion
- May 2026
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0120 in chronic kidney disease (CKD), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Jan 2025; status: active, not recruiting.
02
Drugs
SAL0120
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07716618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07716618.